← Back to Search

Stress and Symptom Management Program 2 for Neurofibromatosis

N/A
Waitlist Available
Led By Ana-Maria Vranceanu, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older
Has a diagnosis of NF1, NF2, or Schwannomatosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 weeks, 8 weeks, 6 months, 12 months
Awards & highlights

Study Summary

This trial will compare two different programs designed to help manage stress and symptoms in patients with neurofibromatosis. The goal is to see which program is more effective in improving quality of life and psychosocial functioning.

Eligible Conditions
  • Neurofibromatosis
  • Schwannomatosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 weeks, 8 weeks, 6 months, 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 weeks, 8 weeks, 6 months, 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Physical Quality of Life
Change in Psychological Quality of Life
Secondary outcome measures
Anxiety
Coping Strategies
Depression
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Stress and Symptom Management Program 2Experimental Treatment1 Intervention
The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
Group II: Stress and Symptom Management Program 1Experimental Treatment1 Intervention
The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,920 Previous Clinical Trials
13,193,084 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis
Ana-Maria Vranceanu, PhDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital
20 Previous Clinical Trials
1,862 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~30 spots leftby Mar 2025